Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

The company’s lead indication area is cardiogenic shock (which is a severe form of heart failure) with istaroxime. Windtree ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, targeting SCAI Stage C ...

By this stage the differential diagnosis had shifted ... typically present with hypotension, cardiomyopathy, or cardiogenic shock when β-adrenergic stimulation overrides α-adrenergic stimulation.

Windtree Therapeutics (WINT) announced the initiation of enrollment in the SEISMiC C trial in SCAI Stage C cardiogenic shock. This study ...

PercAssist, Inc., a medical device company developing innovative technology for extravascular / extracardiac Mechanical ...

Among the various upcoming milestones the company expects to report results from its small Phase 2 cardiogenic shock SCAI ...

is a biotechnology company focused on advancing early and late-stage innovative therapies ... for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart ...

The following is a summary of “Influence of Right and Left Bundle Branch Block in Patients With Cardiogenic Shock and Cardiac ...

Windtree is collaborating with Lee’s on the Phase 3 program and has final signing authority on the protocol. Acute heart failure is the #1 cause of hospitalization in patients >65 years of age in many ...